REGN3767
R3767-ONC-1613
Phase 1 small_molecule completed
Quick answer
REGN3767 for Malignancies is a Phase 1 program (small_molecule) at REGENERON PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- REGENERON PHARMACEUTICALS, INC.
- Indication
- Malignancies
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- completed